Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
2/7/2011
1
New Bo tu l i num
Tox i n s
P r a c t i c eI n t e g r a t i o n
American Academy Of Dermatology, New Orleans, LA
Joel Schlessinger, MD, FAAD, FAACSAdvanced Skin Research Center
DISCLOSURE OF RELEVANTRELATIONSHIPS WITH INDUSTRY
Joel Schlessinger, MD
INTRODUCTION
Advisory Board / ConsultantAbbott Pharma., Allergan, Amgen, Dermik, Galderma, Genentech, Glaxo, Health and Wellness Council of America, Kythera, MEDICIS, Mentor, Merz, MJD Communications, Novartis, Obagi,
Ortho Pharma. (Johnson & Johnson), Stiefel, TheDerm.org,
Researcher3M Pharma., Abbot Pharma., Allergan, Amgen, Astellas, Barrier Therapeutics, Biogen, Centocor,
Clay‐Park Labs, Collagenix, Connetics, Dermik, Dow, ESC Medical, Fujisawa, Galderma, y , g , , , , , j , ,Genentech, Glaxo Pharma., Glenmark Pharma., HealthPoint, Immunex, Ipsen / Inamed, Kythera, MEDICIS, Mentor, Merz, Novartis, Novum, NUCRYST, Ortho Pharma. (Johnson & Johnson), Penederm Pharma., Perrigo, Pfizer, QLT USA, Regeneratio Pharma AG, Sandoz,
Schering Plough, Stiefel Labs, UBC/Vitae
StockholderAllergan, Excel Cosmeceuticals, MEDICIS, J and J, Obagi,
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
2
INTRODUCTION
Demographics in Cosmetic Surgery• 400 participant prospective survey, 84% response rate (n=336)Fi t ti d hi t d f ti
INTRODUCTION
• First prospective demographic study of cosmetic surgery patients
• College degree or greater: 66.9% vs. 28.8% (Census Data, 2008)
• Married: 67.5% vs. 68.9% (Census Data, 2008)• Women older than their partner: 21.7% overall and 50% for fillers vs 14 8% (Census Data 2008)50% for fillers, vs. 14.8% (Census Data, 2008)
• Women younger than their partner: 61.7% overall, vs. 53.3% (Census Data, 2008)
• If older, on average by 6.07 years• If younger, on average by 4.78 years
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
3
New forms of Botulinum Toxin A
• PurTox® – Mentor in conjunction with U of Wisconsin
GENERAL
Wisconsin
• NT‐201/Xeomin® – Merz (Germany)
• Revance ‐ Topically applied
• Others in Brazil, China, Korea under developmentdevelopment
• Crow’s feet studies – various neurotoxins
NamesGENERAL
Commercial Name
Chemical/Trade Name Alternate Names
Botox® onabotulinumtoxinA
Dysport® abobotulinumtoxinA Reloxin®
PurTox®
Revance
Xeomin® incobotulinumtoxinA NT 201, Bocouture® or Xeomeen®
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
4
abobotulinumtoxinA (Dysport®) ‐Glabella
• 50 units in study, but variable in men vs. women
DYSPORT®
• First study to utilize variable unit dosing in men and women
• Areas of injection, five points• Where to go in reality• Youthful patientsL f h d?• Large forehead?
• Crow’s feet?• Better value?• Time of onset?
Actions• Blocks peripheral cholinergic transmission at neuromuscular junction by presynaptic action
DYSPORT®
at a site proximal to the release of acetylcholine
• Antagonist to Calcium related transmitter release
• No effect on post‐ganglionic cholinergic orNo effect on post ganglionic cholinergic or sympathetic transmission
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
5
Further effects• Once bound, attaches rapidly and binds presynaptic nerve membrane
DYSPORT®
• Toxin crosses presynaptic membrane initially• Once toxin inhibits release of acetylcholine by preventing Ca++ mediated acetylcholine release, then decreased endplate potential and paralysisand paralysis
Alternate Nerve Pathways• New nerve terminals
• Eventual contact with post synaptic motor
DYSPORT®
• Eventual contact with post synaptic motor endplate
• Typically 6‐8 weeks, but variable and not complete for up to 4 months or longer in some people
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
6
Areas of Use
• Glabella
• Ocular
DYSPORT®
• Ocular
• Spasmodic Torticollis
• CP
• Hyperhidrosis
Side Effects
• Headache
• Blepharoptosis (injection technique?)
DYSPORT®
• Blepharoptosis (injection technique?)
• Pain/Burning/Stinging
• Facial pain
• Erythema
L l l k• Local muscle weakness
• Edema, bruise, ‘tightness’, paresthesia, nausea
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
7
Pregnancy Category
• No studies have been performed
DYSPORT®
Biology of abobotulinumtoxinA(Dysport®)
l l /
DYSPORT®
• 150 KD molecule/900 KD species
• Constituted in Albumin solution 20%
• Lactose 2.5 mg
• One unit defined as median lethal i t it l d i iintraperitoneal dose in mice
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
8
Storage of Dysport®
• 2 – 8 degrees Celsius
• Refrigerator
DYSPORT®
• Refrigerator
• Up to 8 hours prior to use
• Not to be frozen
• No antimicrobial agent
Published Data• Dysport® vs. Botox® for palmar hyperhidrosis
• 4 to 1 ratio
DYSPORT®
• 4 to 1 ratio
• More improvement with Dysport®, but more side effects noted
• Dosage of 67 units Botox®, 283 Dysport®
• Dysport® more effective during the studyDysport more effective during the study
• British J Derm, 2003
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
9
Cervical Dystonia
• Ratio of 3 to 1 Dysport® to Botox®
• Adverse events:
DYSPORT®
• Adverse events:– Dysport® (58%) vs. Botox® (69%)
• Equivalent results efficacy
• J Neurol Neurosurg Psychiatry, 1998
Glabellar Rhytides
• Randomized trial by Ascher et al
• 25 50 75 units Dysport®
DYSPORT®
• 25, 50, 75 units Dysport®
• Optimal dose felt to be 50 units
• No blepharoptosis noted
• JAAD, 2004
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
10
Diffusion Risks• Hexsel showed that in a ratio of 2.5 to 1 of Dysport® to Botox®, no diffusion differences
DYSPORT®
Dysport to Botox , no diffusion differences
• Study done on upper part of frontal muscles and lateral periorbital
• JAAD, 2005
Treatment
• Dysport® (50 U) or
DYSPORT®
Dysport (50 U) or placebo was administered at five injection points in the glabellar region (10 units/ 0.05 mL per injection point) on Day 0 of each Cycle
20
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
11
Anesthesia – Numya CreamPRACTICE INTEGRATION
Dilution, dilution, dilution• We do 3.0 cc to make it 100 units per 1cc
• Some other groups do 2 5cc
PRACTICE INTEGRATION
• Some other groups do 2.5cc
• Same way to inject
• Same dosages if you use this technique
Dysport® Botox® Dilution
2.5 CCs 2.5 CCs 3:1
Dysport® Botox® Dilution
3.0 CCs 2.5 CCs 2.5:1
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
12
Average Doses of Botox® vs. Dysport®
PRACTICE INTEGRATION
Dysport® Botox®
Forehead/Frontalis 20 U 8 U
Glabella 40 U 16 U
Periorbital 30 U 12 U
DAO 20 U 8 U
Platysma 60‐80 U 24‐32 U
Dysport® vs. Botox®PRACTICE INTEGRATION
Dysport®Botox®
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
13
Dysport®PRACTICE INTEGRATION
Botox®PRACTICE INTEGRATION
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
14
Dysport® vs. Botox® DecappersPRACTICE INTEGRATION
SignagePRACTICE INTEGRATION
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
15
SignagePRACTICE INTEGRATION
Botox® vs. Dysport® –advantage/disadvantage
• Dysport® – Area of spread: Which is it?
BOTOX® vs. DYSPORT®
• Dysport® – Area of spread: Which is it?
• Botox® – Relative familiarity
• Name brand vs. new treatment?
• New ‘wow’ factor
• Not ‘Botox®’• Not ‘Botox®’
• Coming soon…
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
16
Botox® vs. Dysport® –advantage/disadvantage: Glabella
BOTOX® vs. DYSPORT®
• Ease of use – Relatively easy due to guidance• Units – In my practice and in others, 50 Units/male vs. female brow
• Clinical research – Dilution
advantage/disadvantage: Glabella
• New forms ‐ PurTox® and Xeomin® coming?• Rapidity of onset – Question of Dysport® advantage
Botox® vs. Dysport® –advantage/disadvantage
ll d ll d
BOTOX® vs. DYSPORT®
• Hollywood vs. non‐Hollywood
• Upper forehead wrinkles
• Less is more?
• Price!
• Diffusion confusion
• Interest in the public and media
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
17
New areas of treatment• Golf Ball Chin
• DAO
BOTOX® vs. DYSPORT®
• DAO
• Platysma
Areas of concern
• Platysma/neck
• Dysphonia/difficulty swallowing?
BOTOX® vs. DYSPORT®
• Dysphonia/difficulty swallowing?
• New warning labels
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD
2/7/2011
18
Rebates and More
• Rebates for Botox® and Dysport®
• Multiple discounts
BOTOX® vs. DYSPORT®
• Multiple discounts
• Bulk saving
• Latisse® comarketing/filler comarketing
How to approach patients with new treatments
N i i t
BOTOX® vs. DYSPORT®
• Never insist
• Always be open to new ideas
• Offer to try, but make sure it is OK first
• Discuss the overall look and the fact that they are differentare different
Copyr
ight
201
1
Joel
Sch
less
inge
r, MD